A market in transformation
The GLP-1 telehealth market of early 2026 barely resembles the market of early 2025. In 12 months, the regulatory environment, competitive landscape, and patient options underwent fundamental shifts. Here's what happened and what it means for patients.
The FDA enforcement wave
The FDA's enforcement volume against GLP-1 telehealth marketing in 2025–2026 surpassed the cumulative total of the previous decade. In September 2025, the agency issued over 55 warning letters. In March 2026, it issued 30 more. The common thread: telehealth companies marketing compounded GLP-1 medications as equivalent to FDA-approved products — a claim the FDA considers false and misleading because compounded drugs are not reviewed for safety, effectiveness, or quality before being marketed.
In February 2026, HHS escalated beyond warning letters by referring Hims & Hers Health to the Department of Justice. This signaled that enforcement could move from administrative warnings to legal action.
The Hims–Novo Nordisk partnership
Perhaps the most consequential development: on March 9, 2026, Hims & Hers and Novo Nordisk resolved their legal dispute and entered a partnership. Hims will offer Novo Nordisk's branded semaglutide products (Ozempic, Wegovy) on its platform while ceasing most advertising of compounded alternatives. Novo Nordisk dismissed its patent infringement lawsuit. FDA Commissioner Makary publicly endorsed the deal.
This may serve as a template for the industry — telehealth platforms transitioning from compounded to branded products as regulatory pressure mounts and brand-name pricing becomes more accessible through manufacturer programs.
Oral GLP-1 medications arrive
Two new oral GLP-1 medications hit the market in 2025–2026: the Wegovy pill (oral semaglutide dosed for weight loss) and Foundayo (orforglipron), Eli Lilly's once-daily non-peptide oral GLP-1 agonist. Both launched at $149/month — price-competitive with compounded injectables and dramatically cheaper than brand-name injectable pens. These oral options eliminate injection barriers and cold chain shipping requirements, potentially reshaping the telehealth model from "ship a vial" to "send a pill bottle."
Medicare enters the picture
The Medicare GLP-1 Bridge program, launching July 1, 2026, will provide eligible Part D beneficiaries access to GLP-1 medications for weight management at approximately $50 per month. This opens a massive new patient population that was previously locked out by Medicare's prohibition on covering weight-loss medications. Telehealth providers that can navigate Medicare billing and prior authorization will have a significant advantage.
What this means for patients
The net effect of these changes is positive for patients: more options (oral medications, brand-name access through telehealth), lower prices (manufacturer programs, Medicare coverage), and clearer standards (FDA enforcement is raising the floor on provider quality). The trade-off is uncertainty — the regulatory landscape is still shifting, and some compounded providers may exit the market or change their offerings as enforcement continues.
For patients currently on compounded GLP-1 medications through telehealth, the practical advice is: verify your provider's compliance status, understand that your access may evolve as regulations change, and explore whether brand-name options have become cost-competitive with your current compounded regimen. In many cases in 2026, they have.